Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

CytomX Therapeutics (CTMX) Non Operating Income (2016 - 2025)

Historic Non Operating Income for CytomX Therapeutics (CTMX) over the last 12 years, with Q3 2025 value amounting to $5000.0.

  • CytomX Therapeutics' Non Operating Income rose 17142.86% to $5000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $14000.0, marking a year-over-year increase of 22727.27%. This contributed to the annual value of -$38000.0 for FY2024, which is 2666.67% down from last year.
  • According to the latest figures from Q3 2025, CytomX Therapeutics' Non Operating Income is $5000.0, which was up 17142.86% from $17000.0 recorded in Q2 2025.
  • CytomX Therapeutics' 5-year Non Operating Income high stood at $296000.0 for Q2 2022, and its period low was -$82000.0 during Q2 2021.
  • Its 5-year average for Non Operating Income is $11631.6, with a median of $5000.0 in 2021.
  • Its Non Operating Income has fluctuated over the past 5 years, first tumbled by 174000.0% in 2021, then soared by 95000.0% in 2025.
  • Over the past 5 years, CytomX Therapeutics' Non Operating Income (Quarter) stood at $7000.0 in 2021, then tumbled by 85.71% to $1000.0 in 2022, then skyrocketed by 800.0% to $9000.0 in 2023, then tumbled by 311.11% to -$19000.0 in 2024, then skyrocketed by 126.32% to $5000.0 in 2025.
  • Its last three reported values are $5000.0 in Q3 2025, $17000.0 for Q2 2025, and $11000.0 during Q1 2025.